Graves disease
Conditions
Interventions
Placebo group A:methimazole
LA-06 group B:methimazole+Lactobacillus acidophilus06
Sponsors
Weihai Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Symptoms and signs of hyperthyroidism;2. Diffuse thyroid enlargement;3. Decreased serum TSH levels with elevated TT3, FT3, TT4, and FT4;4.Exophthalmos and other infiltrative eye signs;5. Pretibial myxedema;6. Positive TSH receptor antibody (TRAb).Among the above criteria:Items 1-3 are mandatory for diagnosis.Items 4-6 are supportive diagnostic criteria. The patient agrees to participate in this study and signs the informed consent form. The patient is conscious and able to cooperate in completing examinations, questionnaires, medical history collection, etc., either independently or with the assistance of family members.
Exclusion criteria
Exclusion criteria: 1.Pregnant or lactating patients 2.Patients with severe cognitive impairment that affects written and verbal expression, severe aphasia, or dysphasia; 3 . Patients with neurological and psychiatric disorders (degenerative and/or vascular dementia, Parkinson's disease, stroke, and severe depression), severe multi-organ diseases (anemia, lung diseases, cancer) that affect cognition; 4. Patients with other severe physical illnesses or severe abnormalities in liver and kidney function; 5. Patients requiring long-term use of immunosuppressants or those who have taken antibiotics within one month prior to enrollment and during follow-up; 6. Patients who discontinued or arbitrarily adjusted the test sample during follow-up; 7. Patients who concurrently used laxatives such as polyethylene glycol electrolyte, phenolphthalein tablets, senna leaves, etc., during follow-up; 8. Patients with chronic digestive system diseases or tumors, such as peptic ulcer, inflammatory bowel disease, severe liver disease, etc.; 9. Patients who are allergic to the test sample or experience intolerable gastrointestinal symptoms 10. Patients with irregular dietary habits or significant changes in diet during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intestinal function;cognitive ability;Sleep condition;Anxiety;Depression; | — |
Countries
China
Contacts
Public ContactChi Haiyan
Weihai Municipal Hospital
Outcome results
None listed